PressAugust 23, 2024 Revitalist Lifestyle and Wellness Ltd. Sponsors The American Legion 105th National Convention to Combat Veteran Suicide
PressAugust 23, 2024 PharmaDrug’s Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
PressAugust 22, 2024 Bright Green Embarks on Major Partnership With Benuvia Pharmaceuticals Will Supply Pharma Expert With American Made Raw Materials From Its Industry Leading and DEA-Approved SCH I & II Drug Facility
PressAugust 20, 2024 MindBio Therapeutics Corp. Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
PressAugust 20, 2024 PharmaDrug’s Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
PressAugust 20, 2024 Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
PressAugust 16, 2024 Optimi Health Completes Inaugural Export of MDMA Capsules to Australia for PTSD Treatment
PressAugust 15, 2024 Filament Health Announces Second Quarter 2024 Financial Results and Operational Highlights
PressAugust 15, 2024 Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
PressAugust 13, 2024 Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
PressAugust 13, 2024 atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
PressAugust 13, 2024 Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
PressAugust 13, 2024 atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
PressAugust 12, 2024 PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
PressAugust 9, 2024 Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
PressAugust 9, 2024 Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
PressAugust 8, 2024 Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide